Total trials
457
Active
48
Phase 3
5
Total enrollment
4,361,888
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Salmeterol | — | — | — | — | 2 | ||
| Insulin | — | — | — | — | — | 2 | |
| Rapamycin | — | — | — | — | — | 1 | |
| Salmeterol inhalation and urine samples | — | — | — | — | — | 1 | |
| Salmeterol + amino acid availability | — | — | — | — | — | 1 | |
| Salmeterol + placebo | — | — | — | — | — | 1 |
Next readouts
- 2022-12
- 2026-12-18
- 2026-12-31
- 2026-12-31
- 2029-06
Top conditions
- Obesity69
- Healthy42
- Metabolic Syndrome19
- Cardiovascular Disease13
- Insulin Resistance12
- Overweight12
- Dental Caries10
- Insulin Sensitivity10
Frequently asked questions about University of Copenhagen
- How many clinical trials does University of Copenhagen have on ClinicalTrials.gov?
- University of Copenhagen is listed as the lead sponsor on 457 clinical trials in ClinicalTrials.gov, 48 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Copenhagen's trials are in Phase 3?
- 5 of University of Copenhagen's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does University of Copenhagen focus on?
- University of Copenhagen's most-studied conditions on ClinicalTrials.gov are Obesity, Healthy, Metabolic Syndrome, Cardiovascular Disease, Insulin Resistance.
- When are University of Copenhagen's next clinical trial readouts?
- University of Copenhagen has 5 upcoming primary-completion readouts tracked here; the soonest is “Insulin Sensitivity After Breast Cancer”, expected around 2022-12.